Detailed Narrative
Strong FY26 Performance Driven by Strategic Focus
SMS Pharma delivered a robust FY26, with revenue growing 13% to ₹887 crores, supported by strong performance in anti-inflammatory and ARV segments. EBITDA expanded by 23% to ₹171 crores, achieving a 20% margin, primarily due to benefits from backward integration, a favorable product mix, and operating leverage. PAT saw a significant 47% increase to ₹102 crores, including a ₹14 crores contribution from associate company VKT Pharma. The company's focus on increasing market share in key APIs, strengthening backward integration, and diversifying its product portfolio has been instrumental in these results.
Backward Integration and Product Pipeline as Key Growth Drivers
Backward integration, particularly for ibuprofen, has been a critical factor in sustaining and improving EBITDA margins, enabling the company to navigate market scenarios and price escalations. The company filed 12 DMFs and CEPS in FY26 and plans to file 10 more in FY27 and another 10 in FY28, indicating a strong product pipeline. This pipeline, combined with the brownfield expansion, is expected to drive the share of high-value products from the current 47% to approximately 60% in the medium term.
Brownfield Expansion and Capacity Enhancement
The brownfield expansion project, with a total planned investment of ₹280 crores (₹130 crores already invested), is on track for completion by March FY27. This expansion includes increasing ibuprofen capacity from 500 tons to 800 metric tons per month and establishing a dedicated block for 4-5 new high-value, high-margin APIs. These investments are anticipated to generate incremental revenues from FY28, with capacity utilization expected to reach high levels by FY28.
Peptides and CDMO Initiatives for Future Growth
SMS Pharma is making encouraging progress in peptides, with promising R&D results and multiple products under development. The company expects to provide greater clarity on the commercial roadmap for peptides after the next two quarters, with meaningful contributions projected from FY29. Similarly, CDMO initiatives remain a strategic focus, with the project progressing well, and a more comprehensive update is expected after the next two quarters. These initiatives, alongside core API business and new product launches, are seen as strong platforms for sustainable growth through FY30 and beyond.
Conservative FY27 Outlook Amidst Geopolitical Headwinds
Despite strong FY26 performance, the company is adopting a prudent approach for FY27 due to geopolitical developments in the Middle East, which have created uncertainties in logistics, freight, and supply chain stability. Management is guiding for a conservative 15% revenue growth and aiming to maintain its FY26 EBITDA margin of 20% in FY27, with a long-term target of 20-25%. However, they note potential for higher growth if external conditions stabilize.